Targeting CXCR7 increases anticoagulant long-chain acylcarnitines in platelets and reduces thrombotic activity, offering a potential therapeutic approach for thrombosis.
Antiplatelet Therapy and Cardiovascular Diseases
Moving in New England Journal of Medicine, Blood, Nature Medicine.
- Moved this week
- 0
Rebuilt
Moved this week
Nothing in this area has moved yet this week.
Latest in Antiplatelet Therapy and Cardiovascular Diseases
Newest first · last 60 days
Potent P2Y12 inhibitors combined with DOACs increase bleeding risk without reducing ischemic events in atrial fibrillation and acute coronary syndrome patients.
- Open access
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4